{
  "id": "42_ref_0",
  "query": "对象：Floxuridine（5-氟脱氧尿苷）；SMILES：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O。已知理化性质：MW=246.2、logP=-0.9、TPSA=92.0、HBD=3、HBA=5、RB=4。3D几何优化：方法ETKDG、力场MMFF、最大迭代500、收敛=true、总能量72.8 kcal/mol。3D形状描述符：Rg=2.35、PMI=[120.4, 230.8, 350.9]、asphericity=0.24、eccentricity=0.78。合成可及性原始分数：SAS_raw=4.7。可视化路径：2D=\"/images/Floxuridine_2D.png\"；3D=\"/models/Floxuridine_3D.sdf\"。\n(1) 报告MW、logP、TPSA、HBD、HBA、RB，并对Lipinski五规则进行两次独立评估，分别给出违例数，说明两次结果是否相同。\n(2) 报告3D几何优化的方法、力场、最大迭代、收敛与总能量，并给出Rg、PMI、asphericity、eccentricity。\n(3) 将SAS_raw按四舍五入保留1位小数，给出最终SAS分数，并说明来源为题面给定且进行[1,10]范围检查。\n(4) 给出2D/3D结构图路径，并说明其用于核对嘧啶5位氟取代与糖环手性（相对构型）。\n(5) 提供数值汇总与交叉校验清单（含SAS范围检查、理化属性重复评估结果是否相同、形状与理化属性的合理性说明），并给出总体成药性结论与最终SAS。\n结果以数值形式报告；SAS保留1位小数；所有量按题面给定单位与数值呈现；未注明单位的量视为无单位。",
  "model": "gpt-5",
  "use_tools": false,
  "mode": "text_mode",
  "rounds": 1,
  "messages": [
    {
      "role": "user",
      "content": "对象：Floxuridine（5-氟脱氧尿苷）；SMILES：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O。已知理化性质：MW=246.2、logP=-0.9、TPSA=92.0、HBD=3、HBA=5、RB=4。3D几何优化：方法ETKDG、力场MMFF、最大迭代500、收敛=true、总能量72.8 kcal/mol。3D形状描述符：Rg=2.35、PMI=[120.4, 230.8, 350.9]、asphericity=0.24、eccentricity=0.78。合成可及性原始分数：SAS_raw=4.7。可视化路径：2D=\"/images/Floxuridine_2D.png\"；3D=\"/models/Floxuridine_3D.sdf\"。\n(1) 报告MW、logP、TPSA、HBD、HBA、RB，并对Lipinski五规则进行两次独立评估，分别给出违例数，说明两次结果是否相同。\n(2) 报告3D几何优化的方法、力场、最大迭代、收敛与总能量，并给出Rg、PMI、asphericity、eccentricity。\n(3) 将SAS_raw按四舍五入保留1位小数，给出最终SAS分数，并说明来源为题面给定且进行[1,10]范围检查。\n(4) 给出2D/3D结构图路径，并说明其用于核对嘧啶5位氟取代与糖环手性（相对构型）。\n(5) 提供数值汇总与交叉校验清单（含SAS范围检查、理化属性重复评估结果是否相同、形状与理化属性的合理性说明），并给出总体成药性结论与最终SAS。\n结果以数值形式报告；SAS保留1位小数；所有量按题面给定单位与数值呈现；未注明单位的量视为无单位。"
    },
    {
      "role": "assistant",
      "content": "(1) 理化性质与Lipinski五规则评估\n- MW=246.2\n- logP=-0.9\n- TPSA=92.0\n- HBD=3\n- HBA=5\n- RB=4\n- Lipinski评估A：违例数=0\n- Lipinski评估B：违例数=0\n- 两次评估结果是否相同=是\n\n(2) 3D几何优化与形状描述符\n- 几何优化方法=ETKDG\n- 力场=MMFF\n- 最大迭代=500\n- 收敛=true\n- 总能量=72.8 kcal/mol\n- Rg=2.35\n- PMI=[120.4, 230.8, 350.9]\n- asphericity=0.24\n- eccentricity=0.78\n\n(3) 合成可及性分数\n- SAS_raw=4.7\n- 四舍五入保留1位小数后的最终SAS=4.7\n- 来源=题面给定\n- 范围检查[1,10]=通过\n\n(4) 结构图路径与用途\n- 2D结构图路径=/images/Floxuridine_2D.png\n- 3D结构模型路径=/models/Floxuridine_3D.sdf\n- 用途=核对嘧啶5位氟取代与糖环手性（相对构型）\n\n(5) 数值汇总与交叉校验清单、总体结论\n- SAS范围检查结果=通过（1≤4.7≤10）\n- 理化属性重复评估（Lipinski）结果是否相同=是（A违例数=0；B违例数=0）\n- 形状与理化属性合理性说明（数值一致性判定）：\n  - 低MW=246.2、低logP=-0.9 ↔ Rg=2.35（小分子体量合理）\n  - TPSA=92.0（中等极性）↔ asphericity=0.24、eccentricity=0.78（中度各向异性/一定细长度）\n  - 合理性判定=是\n- 总体成药性结论=符合Lipinski（0违例）；口服成药性潜力良好（渗透性可能受较高极性与糖环影响）\n- 最终SAS=4.7"
    },
    {
      "role": "user",
      "content": "现在请仅输出严格 JSON，必须完全匹配以下结构（键名、层级、字段齐全），所有数值用数字表示（保留2-3位小数），布尔用 true/false，字符串填写说明文字。不要输出任何解释文字或前后缀，也不要多余字段；若无法计算某值请给出可解析的近似值。\n\n{\n  \"(1)\": {\n    \"MW\": \"[数值]\",\n    \"logP\": \"[数值]\",\n    \"TPSA\": \"[数值]\",\n    \"HBD\": \"[数值]\",\n    \"HBA\": \"[数值]\",\n    \"RB\": \"[数值]\",\n    \"Lipinski_violations_eval_1\": \"[数值]\",\n    \"Lipinski_violations_eval_2\": \"[数值]\",\n    \"result_relation\": \"[字符串]\"\n  },\n  \"(2)\": {\n    \"optimization_method\": \"[字符串]\",\n    \"force_field\": \"[字符串]\",\n    \"max_iterations\": \"[数值]\",\n    \"converged\": \"[布尔值]\",\n    \"total_energy\": \"[字符串]\",\n    \"Rg\": \"[数值]\",\n    \"PMI\": \"[3个数值的数组]\",\n    \"asphericity\": \"[数值]\",\n    \"eccentricity\": \"[数值]\"\n  },\n  \"(3)\": {\n    \"SAS_raw\": \"[数值]\",\n    \"SAS_final_1dp\": \"[数值]\",\n    \"source\": \"[字符串]\",\n    \"range_check\": \"[字符串]\"\n  },\n  \"(4)\": {\n    \"path_2D\": \"[字符串]\",\n    \"path_3D\": \"[字符串]\",\n    \"usage\": \"[字符串]\"\n  },\n  \"(5)\": {\n    \"summary_index\": {\n      \"P1\": \"[字符串]\",\n      \"G1\": \"[字符串]\",\n      \"S1\": \"[字符串]\",\n      \"Paths\": \"[字符串]\"\n    },\n    \"cross_checks\": \"[3个字符串的数组]\",\n    \"overall_conclusion\": \"[字符串]\"\n  }\n}"
    },
    {
      "role": "assistant",
      "content": "{\n  \"(1)\": {\n    \"MW\": 246.200,\n    \"logP\": -0.900,\n    \"TPSA\": 92.000,\n    \"HBD\": 3.000,\n    \"HBA\": 5.000,\n    \"RB\": 4.000,\n    \"Lipinski_violations_eval_1\": 0.000,\n    \"Lipinski_violations_eval_2\": 0.000,\n    \"result_relation\": \"两次评估结果相同（均为0违例）\"\n  },\n  \"(2)\": {\n    \"optimization_method\": \"ETKDG\",\n    \"force_field\": \"MMFF\",\n    \"max_iterations\": 500.000,\n    \"converged\": true,\n    \"total_energy\": \"72.800 kcal/mol\",\n    \"Rg\": 2.350,\n    \"PMI\": [120.400, 230.800, 350.900],\n    \"asphericity\": 0.240,\n    \"eccentricity\": 0.780\n  },\n  \"(3)\": {\n    \"SAS_raw\": 4.700,\n    \"SAS_final_1dp\": 4.700,\n    \"source\": \"题面给定\",\n    \"range_check\": \"已检查范围[1,10]：通过\"\n  },\n  \"(4)\": {\n    \"path_2D\": \"/images/Floxuridine_2D.png\",\n    \"path_3D\": \"/models/Floxuridine_3D.sdf\",\n    \"usage\": \"用于核对嘧啶5位氟取代与糖环手性（相对构型）\"\n  },\n  \"(5)\": {\n    \"summary_index\": {\n      \"P1\": \"理化性质与Lipinski评估汇总完成\",\n      \"G1\": \"3D优化参数与形状描述符汇总完成\",\n      \"S1\": \"SAS取值与范围检查汇总完成\",\n      \"Paths\": \"2D/3D结构路径用于结构与构型核对\"\n    },\n    \"cross_checks\": [\"SAS范围[1,10]检查通过\", \"两次Lipinski违例计数一致\", \"形状与理化属性合理性良好\"],\n    \"overall_conclusion\": \"符合Lipinski（0违例），整体成药性潜力良好；最终SAS=4.700\"\n  }\n}"
    }
  ],
  "answer_template": {
    "(1)": {
      "MW": "[数值]",
      "logP": "[数值]",
      "TPSA": "[数值]",
      "HBD": "[数值]",
      "HBA": "[数值]",
      "RB": "[数值]",
      "Lipinski_violations_eval_1": "[数值]",
      "Lipinski_violations_eval_2": "[数值]",
      "result_relation": "[字符串]"
    },
    "(2)": {
      "optimization_method": "[字符串]",
      "force_field": "[字符串]",
      "max_iterations": "[数值]",
      "converged": "[布尔值]",
      "total_energy": "[字符串]",
      "Rg": "[数值]",
      "PMI": "[3个数值的数组]",
      "asphericity": "[数值]",
      "eccentricity": "[数值]"
    },
    "(3)": {
      "SAS_raw": "[数值]",
      "SAS_final_1dp": "[数值]",
      "source": "[字符串]",
      "range_check": "[字符串]"
    },
    "(4)": {
      "path_2D": "[字符串]",
      "path_3D": "[字符串]",
      "usage": "[字符串]"
    },
    "(5)": {
      "summary_index": {
        "P1": "[字符串]",
        "G1": "[字符串]",
        "S1": "[字符串]",
        "Paths": "[字符串]"
      },
      "cross_checks": "[3个字符串的数组]",
      "overall_conclusion": "[字符串]"
    }
  },
  "golden_standard": {
    "(1)": {
      "MW": 246.2,
      "logP": -0.9,
      "TPSA": 92.0,
      "HBD": 3,
      "HBA": 5,
      "RB": 4,
      "Lipinski_violations_eval_1": 0,
      "Lipinski_violations_eval_2": 0,
      "result_relation": "两次结果相同（均满足规则）"
    },
    "(2)": {
      "optimization_method": "ETKDG",
      "force_field": "MMFF",
      "max_iterations": 500,
      "converged": true,
      "total_energy": "72.8 kcal/mol",
      "Rg": 2.35,
      "PMI": [
        120.4,
        230.8,
        350.9
      ],
      "asphericity": 0.24,
      "eccentricity": 0.78
    },
    "(3)": {
      "SAS_raw": 4.7,
      "SAS_final_1dp": 4.7,
      "source": "题面给定SAS_raw",
      "range_check": "[1,10]内"
    },
    "(4)": {
      "path_2D": "/images/Floxuridine_2D.png",
      "path_3D": "/models/Floxuridine_3D.sdf",
      "usage": "2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性"
    },
    "(5)": {
      "summary_index": {
        "P1": "(1)中的理化性质与Lipinski评估结果",
        "G1": "(2)中的几何优化与形状描述符",
        "S1": "(3)中的最终SAS",
        "Paths": "(4)中的2D/3D路径"
      },
      "cross_checks": [
        "SAS范围：S1∈[1,10]",
        "Lipinski两次评估结果相同，均满足规则",
        "理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征"
      ],
      "overall_conclusion": "满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征"
    }
  },
  "expected_format": "structured_json",
  "model_structured_answer": {
    "(1)": {
      "MW": 246.2,
      "logP": -0.9,
      "TPSA": 92.0,
      "HBD": 3.0,
      "HBA": 5.0,
      "RB": 4.0,
      "Lipinski_violations_eval_1": 0.0,
      "Lipinski_violations_eval_2": 0.0,
      "result_relation": "两次评估结果相同（均为0违例）"
    },
    "(2)": {
      "optimization_method": "ETKDG",
      "force_field": "MMFF",
      "max_iterations": 500.0,
      "converged": true,
      "total_energy": "72.800 kcal/mol",
      "Rg": 2.35,
      "PMI": [
        120.4,
        230.8,
        350.9
      ],
      "asphericity": 0.24,
      "eccentricity": 0.78
    },
    "(3)": {
      "SAS_raw": 4.7,
      "SAS_final_1dp": 4.7,
      "source": "题面给定",
      "range_check": "已检查范围[1,10]：通过"
    },
    "(4)": {
      "path_2D": "/images/Floxuridine_2D.png",
      "path_3D": "/models/Floxuridine_3D.sdf",
      "usage": "用于核对嘧啶5位氟取代与糖环手性（相对构型）"
    },
    "(5)": {
      "summary_index": {
        "P1": "理化性质与Lipinski评估汇总完成",
        "G1": "3D优化参数与形状描述符汇总完成",
        "S1": "SAS取值与范围检查汇总完成",
        "Paths": "2D/3D结构路径用于结构与构型核对"
      },
      "cross_checks": [
        "SAS范围[1,10]检查通过",
        "两次Lipinski违例计数一致",
        "形状与理化属性合理性良好"
      ],
      "overall_conclusion": "符合Lipinski（0违例），整体成药性潜力良好；最终SAS=4.700"
    }
  },
  "answer_extraction_success": true,
  "model_raw_answer": "{\n  \"(1)\": {\n    \"MW\": 246.200,\n    \"logP\": -0.900,\n    \"TPSA\": 92.000,\n    \"HBD\": 3.000,\n    \"HBA\": 5.000,\n    \"RB\": 4.000,\n    \"Lipinski_violations_eval_1\": 0.000,\n    \"Lipinski_violations_eval_2\": 0.000,\n    \"result_relation\": \"两次评估结果相同（均为0违例）\"\n  },\n  \"(2)\": {\n    \"optimization_method\": \"ETKDG\",\n    \"force_field\": \"MMFF\",\n    \"max_iterations\": 500.000,\n    \"converged\": true,\n    \"total_energy\": \"72.800 kcal/mol\",\n    \"Rg\": 2.350,\n    \"PMI\": [120.400, 230.800, 350.900],\n    \"asphericity\": 0.240,\n    \"eccentricity\": 0.780\n  },\n  \"(3)\": {\n    \"SAS_raw\": 4.700,\n    \"SAS_final_1dp\": 4.700,\n    \"source\": \"题面给定\",\n    \"range_check\": \"已检查范围[1,10]：通过\"\n  },\n  \"(4)\": {\n    \"path_2D\": \"/images/Floxuridine_2D.png\",\n    \"path_3D\": \"/models/Floxuridine_3D.sdf\",\n    \"usage\": \"用于核对嘧啶5位氟取代与糖环手性（相对构型）\"\n  },\n  \"(5)\": {\n    \"summary_index\": {\n      \"P1\": \"理化性质与Lipinski评估汇总完成\",\n      \"G1\": \"3D优化参数与形状描述符汇总完成\",\n      \"S1\": \"SAS取值与范围检查汇总完成\",\n      \"Paths\": \"2D/3D结构路径用于结构与构型核对\"\n    },\n    \"cross_checks\": [\"SAS范围[1,10]检查通过\", \"两次Lipinski违例计数一致\", \"形状与理化属性合理性良好\"],\n    \"overall_conclusion\": \"符合Lipinski（0违例），整体成药性潜力良好；最终SAS=4.700\"\n  }\n}",
  "model_last_assistant_message": {
    "role": "assistant",
    "content": "{\n  \"(1)\": {\n    \"MW\": 246.200,\n    \"logP\": -0.900,\n    \"TPSA\": 92.000,\n    \"HBD\": 3.000,\n    \"HBA\": 5.000,\n    \"RB\": 4.000,\n    \"Lipinski_violations_eval_1\": 0.000,\n    \"Lipinski_violations_eval_2\": 0.000,\n    \"result_relation\": \"两次评估结果相同（均为0违例）\"\n  },\n  \"(2)\": {\n    \"optimization_method\": \"ETKDG\",\n    \"force_field\": \"MMFF\",\n    \"max_iterations\": 500.000,\n    \"converged\": true,\n    \"total_energy\": \"72.800 kcal/mol\",\n    \"Rg\": 2.350,\n    \"PMI\": [120.400, 230.800, 350.900],\n    \"asphericity\": 0.240,\n    \"eccentricity\": 0.780\n  },\n  \"(3)\": {\n    \"SAS_raw\": 4.700,\n    \"SAS_final_1dp\": 4.700,\n    \"source\": \"题面给定\",\n    \"range_check\": \"已检查范围[1,10]：通过\"\n  },\n  \"(4)\": {\n    \"path_2D\": \"/images/Floxuridine_2D.png\",\n    \"path_3D\": \"/models/Floxuridine_3D.sdf\",\n    \"usage\": \"用于核对嘧啶5位氟取代与糖环手性（相对构型）\"\n  },\n  \"(5)\": {\n    \"summary_index\": {\n      \"P1\": \"理化性质与Lipinski评估汇总完成\",\n      \"G1\": \"3D优化参数与形状描述符汇总完成\",\n      \"S1\": \"SAS取值与范围检查汇总完成\",\n      \"Paths\": \"2D/3D结构路径用于结构与构型核对\"\n    },\n    \"cross_checks\": [\"SAS范围[1,10]检查通过\", \"两次Lipinski违例计数一致\", \"形状与理化属性合理性良好\"],\n    \"overall_conclusion\": \"符合Lipinski（0违例），整体成药性潜力良好；最终SAS=4.700\"\n  }\n}"
  },
  "evaluation_score": 0.9714285714285714,
  "evaluation_summary": "匹配字段: 34/35 (得分: 97.14%)",
  "evaluation_details": {
    "(1).MW": {
      "path": "(1).MW",
      "expected": 246.2,
      "actual": 246.2,
      "expected_num": 246.2,
      "actual_num": 246.2,
      "status": "match",
      "match_type": "exact"
    },
    "(1).logP": {
      "path": "(1).logP",
      "expected": -0.9,
      "actual": -0.9,
      "expected_num": -0.9,
      "actual_num": -0.9,
      "status": "match",
      "match_type": "exact"
    },
    "(1).TPSA": {
      "path": "(1).TPSA",
      "expected": 92.0,
      "actual": 92.0,
      "expected_num": 92.0,
      "actual_num": 92.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).HBD": {
      "path": "(1).HBD",
      "expected": 3,
      "actual": 3.0,
      "expected_num": 3.0,
      "actual_num": 3.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).HBA": {
      "path": "(1).HBA",
      "expected": 5,
      "actual": 5.0,
      "expected_num": 5.0,
      "actual_num": 5.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).RB": {
      "path": "(1).RB",
      "expected": 4,
      "actual": 4.0,
      "expected_num": 4.0,
      "actual_num": 4.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).Lipinski_violations_eval_1": {
      "path": "(1).Lipinski_violations_eval_1",
      "expected": 0,
      "actual": 0.0,
      "expected_num": 0.0,
      "actual_num": 0.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).Lipinski_violations_eval_2": {
      "path": "(1).Lipinski_violations_eval_2",
      "expected": 0,
      "actual": 0.0,
      "expected_num": 0.0,
      "actual_num": 0.0,
      "status": "match",
      "match_type": "exact"
    },
    "(1).result_relation": {
      "path": "(1).result_relation",
      "expected": "两次结果相同（均满足规则）",
      "actual": "两次评估结果相同（均为0违例）",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(2).optimization_method": {
      "path": "(2).optimization_method",
      "expected": "ETKDG",
      "actual": "ETKDG",
      "status": "match",
      "match_type": "exact"
    },
    "(2).force_field": {
      "path": "(2).force_field",
      "expected": "MMFF",
      "actual": "MMFF",
      "status": "match",
      "match_type": "exact"
    },
    "(2).max_iterations": {
      "path": "(2).max_iterations",
      "expected": 500,
      "actual": 500.0,
      "expected_num": 500.0,
      "actual_num": 500.0,
      "status": "match",
      "match_type": "exact"
    },
    "(2).converged": {
      "path": "(2).converged",
      "expected": true,
      "actual": true,
      "expected_num": 1.0,
      "actual_num": 1.0,
      "status": "match",
      "match_type": "exact"
    },
    "(2).total_energy": {
      "path": "(2).total_energy",
      "expected": "72.8 kcal/mol",
      "actual": "72.800 kcal/mol",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(2).Rg": {
      "path": "(2).Rg",
      "expected": 2.35,
      "actual": 2.35,
      "expected_num": 2.35,
      "actual_num": 2.35,
      "status": "match",
      "match_type": "exact"
    },
    "(2).PMI[0]": {
      "path": "(2).PMI[0]",
      "expected": 120.4,
      "actual": 120.4,
      "expected_num": 120.4,
      "actual_num": 120.4,
      "status": "match",
      "match_type": "exact"
    },
    "(2).PMI[1]": {
      "path": "(2).PMI[1]",
      "expected": 230.8,
      "actual": 230.8,
      "expected_num": 230.8,
      "actual_num": 230.8,
      "status": "match",
      "match_type": "exact"
    },
    "(2).PMI[2]": {
      "path": "(2).PMI[2]",
      "expected": 350.9,
      "actual": 350.9,
      "expected_num": 350.9,
      "actual_num": 350.9,
      "status": "match",
      "match_type": "exact"
    },
    "(2).asphericity": {
      "path": "(2).asphericity",
      "expected": 0.24,
      "actual": 0.24,
      "expected_num": 0.24,
      "actual_num": 0.24,
      "status": "match",
      "match_type": "exact"
    },
    "(2).eccentricity": {
      "path": "(2).eccentricity",
      "expected": 0.78,
      "actual": 0.78,
      "expected_num": 0.78,
      "actual_num": 0.78,
      "status": "match",
      "match_type": "exact"
    },
    "(3).SAS_raw": {
      "path": "(3).SAS_raw",
      "expected": 4.7,
      "actual": 4.7,
      "expected_num": 4.7,
      "actual_num": 4.7,
      "status": "match",
      "match_type": "exact"
    },
    "(3).SAS_final_1dp": {
      "path": "(3).SAS_final_1dp",
      "expected": 4.7,
      "actual": 4.7,
      "expected_num": 4.7,
      "actual_num": 4.7,
      "status": "match",
      "match_type": "exact"
    },
    "(3).source": {
      "path": "(3).source",
      "expected": "题面给定SAS_raw",
      "actual": "题面给定",
      "status": "mismatch",
      "match_type": "secondary_llm_failed"
    },
    "(3).range_check": {
      "path": "(3).range_check",
      "expected": "[1,10]内",
      "actual": "已检查范围[1,10]：通过",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(4).path_2D": {
      "path": "(4).path_2D",
      "expected": "/images/Floxuridine_2D.png",
      "actual": "/images/Floxuridine_2D.png",
      "status": "match",
      "match_type": "exact"
    },
    "(4).path_3D": {
      "path": "(4).path_3D",
      "expected": "/models/Floxuridine_3D.sdf",
      "actual": "/models/Floxuridine_3D.sdf",
      "status": "match",
      "match_type": "exact"
    },
    "(4).usage": {
      "path": "(4).usage",
      "expected": "2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性",
      "actual": "用于核对嘧啶5位氟取代与糖环手性（相对构型）",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).summary_index.P1": {
      "path": "(5).summary_index.P1",
      "expected": "(1)中的理化性质与Lipinski评估结果",
      "actual": "理化性质与Lipinski评估汇总完成",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).summary_index.G1": {
      "path": "(5).summary_index.G1",
      "expected": "(2)中的几何优化与形状描述符",
      "actual": "3D优化参数与形状描述符汇总完成",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).summary_index.S1": {
      "path": "(5).summary_index.S1",
      "expected": "(3)中的最终SAS",
      "actual": "SAS取值与范围检查汇总完成",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).summary_index.Paths": {
      "path": "(5).summary_index.Paths",
      "expected": "(4)中的2D/3D路径",
      "actual": "2D/3D结构路径用于结构与构型核对",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).cross_checks[0]": {
      "path": "(5).cross_checks[0]",
      "expected": "SAS范围：S1∈[1,10]",
      "actual": "SAS范围[1,10]检查通过",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).cross_checks[1]": {
      "path": "(5).cross_checks[1]",
      "expected": "Lipinski两次评估结果相同，均满足规则",
      "actual": "两次Lipinski违例计数一致",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).cross_checks[2]": {
      "path": "(5).cross_checks[2]",
      "expected": "理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征",
      "actual": "形状与理化属性合理性良好",
      "status": "match",
      "match_type": "secondary_llm_verification"
    },
    "(5).overall_conclusion": {
      "path": "(5).overall_conclusion",
      "expected": "满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征",
      "actual": "符合Lipinski（0违例），整体成药性潜力良好；最终SAS=4.700",
      "status": "match",
      "match_type": "secondary_llm_verification"
    }
  },
  "metadata": {
    "subject": "化学",
    "topic": "药物化学与合成可及性",
    "image_path": [],
    "solution_steps": [
      "【分子识别与解析】解析5-Fluorodeoxyuridine的SMILES字符串：OC[C@H]1O[C@H](C[C@@H]1O)N2C=C(F)C(=O)NC2=O",
      "【SAS计算】调用 calculate_synthetic_accessibility(smiles) 使用Ertl-Schuffenhauer算法计算合成可及性分数",
      "SAS基于分子复杂度、环系统、立体化学和已知合成片段进行统计评估",
      "获得SAS = 3.5，对应\"相对容易合成\"（2.0-4.0范围）",
      "【理化性质分析】调用 mol_basic_physicochemical_info(smiles) 获取完整的分子信息",
      "分子式：C9H11FN2O5，分子量：246.07 g/mol",
      "LogP = -1.68（亲水性强），TPSA = 104.55 Å²（极性表面积大）",
      "氢键供体：3，氢键受体：6，可旋转键：2",
      "芳香环：1（嘧啶环），总环数：2（嘧啶环+糖环）",
      "【Lipinski成药性评估】检查Lipinski五规则的违规情况",
      "✓ MW(246.07) ≤ 500，✓ LogP(-1.68) ≤ 5，✓ HBD(3) ≤ 5，✓ HBA(6) ≤ 10",
      "违规数 = 0，类药性 = ✓ 是",
      "【3D可视化】调用 chem_visualizer 生成2D结构图和3D投影图",
      "生成图像：5_Fluorodeoxyuridine_2d.png（平面结构）",
      "5_Fluorodeoxyuridine_3d_projection.png（3D投影）",
      "5_Fluorodeoxyuridine_3d_matplotlib.png（3D立体图）",
      "【3D结构优化】调用 optimize_geometry(smiles, method='ETKDGv3', force_field='MMFF', max_iters=200)",
      "初始能量：-0.55 kcal/mol → 优化后能量：-30.79 kcal/mol",
      "能量降低：ΔE = -30.24 kcal/mol（结构显著稳定化）",
      "【3D性质计算】调用 get_3d_properties(smiles, method='ETKDGv3', conf_id=0)",
      "主惯性矩：PMI1=496.58, PMI2=2099.67, PMI3=2215.85 amu·Ų",
      "归一化惯性矩比：NPR1=0.224, NPR2=0.948",
      "分子形状：极端棒状/纤维状（NPR1<0.5, NPR2>0.95）",
      "回转半径：Rg = 3.126 Å（分子尺寸的特征长度）",
      "非球形度：asphericity = 0.478（显著偏离球形）",
      "偏心率：eccentricity = 0.975（高度拉伸的椭球形）",
      "【合成难度评估】根据SAS=3.5给出合成难度评价",
      "合成难度：相对容易合成（★★☆☆☆）",
      "核苷类似物的典型复杂度，适合药物开发",
      "【药物应用背景】5-FdU是胸苷酸合成酶抑制剂，用于治疗结直肠癌和肝癌",
      "商品名：Floxuridine, FUDR",
      "作用机制：干扰DNA合成，诱导癌细胞凋亡",
      "【最终答案】合成可及性分数 SAS = 3.5"
    ],
    "tool_expected": [
      "calculate_synthetic_accessibility",
      "mol_basic_physicochemical_info",
      "chem_visualizer",
      "optimize_geometry",
      "get_3d_properties"
    ],
    "golden_answer": [
      {
        "(1)": {
          "MW": 246.2,
          "logP": -0.9,
          "TPSA": 92.0,
          "HBD": 3,
          "HBA": 5,
          "RB": 4,
          "Lipinski_violations_eval_1": 0,
          "Lipinski_violations_eval_2": 0,
          "result_relation": "两次结果相同（均满足规则）"
        },
        "(2)": {
          "optimization_method": "ETKDG",
          "force_field": "MMFF",
          "max_iterations": 500,
          "converged": true,
          "total_energy": "72.8 kcal/mol",
          "Rg": 2.35,
          "PMI": [
            120.4,
            230.8,
            350.9
          ],
          "asphericity": 0.24,
          "eccentricity": 0.78
        },
        "(3)": {
          "SAS_raw": 4.7,
          "SAS_final_1dp": 4.7,
          "source": "题面给定SAS_raw",
          "range_check": "[1,10]内"
        },
        "(4)": {
          "path_2D": "/images/Floxuridine_2D.png",
          "path_3D": "/models/Floxuridine_3D.sdf",
          "usage": "2D用于定位嘧啶5位F取代；3D用于查看糖环立体中心以核对手性"
        },
        "(5)": {
          "summary_index": {
            "P1": "(1)中的理化性质与Lipinski评估结果",
            "G1": "(2)中的几何优化与形状描述符",
            "S1": "(3)中的最终SAS",
            "Paths": "(4)中的2D/3D路径"
          },
          "cross_checks": [
            "SAS范围：S1∈[1,10]",
            "Lipinski两次评估结果相同，均满足规则",
            "理化性质与形状合理性：低logP与较高TPSA提示亲水性；PMI与asphericity显示非球形核苷骨架，符合含糖嘧啶结构特征"
          ],
          "overall_conclusion": "满足Lipinski五规则且两次评估相同；SAS为S1，显示中等合成可及性；具备口服药物样特征"
        }
      }
    ],
    "original_question_id": "42",
    "test_type": "refined"
  },
  "metadata_summary": {
    "subject": "化学",
    "topic": "药物化学与合成可及性",
    "test_type": "refined",
    "original_question_id": "42",
    "subject_topic_key": "化学::药物化学与合成可及性"
  },
  "evaluation_score_segments": {
    "0_25": 1.0,
    "0_50": 1.0,
    "0_75": 0.9629629629629629,
    "0_100": 0.9714285714285714
  }
}